TL;DR
The potential of ZnO NPs are demonstrated as effective, concentration-dependent anti-biofilm agents with gene-targeted antimicrobial activity, supporting their advancement for nano biomedical applications against multi drug resistance pathogens.
Results show that green-synthesized ZnO nanoparticles have strong antibacterial and antibiofilm potential and can boost the effectiveness of traditional antibiotics, indicating their potential as supplemental agents in MDR bacterial infection management strategies.
It is suggested that biogenically synthesized MgO NPs hold considerable promise as antibacterial and antibiofilm agents against MDR Gram-negative pathogens.
Findings highlight ZnONPs as a promising, low-cost alternative for managing MRSA infections, particularly in biofilm-associated cases, warranting further clinical exploration in resource-limited settings.
ZnO NPs showed both antibacterial and antibiofilm efficacy against drug-resistant strains of E. coli, K. pneumoniae, and S. aureus and completely eradicated E. coli biofilm in combination with gentamicin.
P. graveolens EO, citronellol, and geraniol exhibited promising anti-virulence properties against multidrug-resistant uropathogenic P. aeruginosa, supporting their potential as complementary agents for controlling biofilm- and motility-associated infections.
Bacteriocin Basin exhibits dual bioactivity by attenuating key virulence pathways in E. faecalis and exerting cytotoxic and anti-inflammatory effects on KB (HeLa-derived) cells, providing a preliminary in vitro foundation for exploring the dual bioactivity of bacteriocin Basin.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
